03 Feb Takenaka Partners Advises Kobayashi on its Acquisition of Alva-Amco
Takenaka Partners LLC (Los Angeles, CA) acted as the exclusive financial advisor to Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) (“Kobayashi”) on its acquisition of Alva-Amco Pharmacal Companies, Inc. (“Alva-Amco”), in cooperation with Yamada Consulting Group Co., Ltd.
Kobayashi, founded in 1886 and based in Osaka, Japan, produces well-branded products, including over-the-counter (OTC) medicines, oral hygiene products, and household products like deodorizing air fresheners, in Japan and internationally.
Alva-Amco, founded in 1904 and based in Niles, Illinois, is a leading provider of branded OTC consumer health products across a number of product categories, including skin care, women’s health, antifungals, upset stomach and pain treatments. Its portfolio of brands is sold at pharmacies and mass merchants throughout North America.
Kobayashi views international business as an important growth driver and has already established local subsidiaries in the United States, the United Kingdom, China, and other Asian countries. This partnership will allow Kobayashi to leverage its own R&D expertise and Alva-Amco’s brand, marketing, and sales capabilities to provide added value to customers and further develop and expand its OTC pharmaceutical business in North America.
Yukuo Takenaka, President and CEO of Takenaka Partners, stated, “Takenaka Partners is pleased to have played a key role in facilitating a strong relationship between Kobayashi and Alva-Amco, especially during these challenging times of COVID-19. This synergistic alliance will allow Kobayashi to further expand its global operations and achieve its goals. We look forward to watching both companies grow in the future.”